
CATX Stock Forecast & Price Target
CATX Analyst Ratings
Bulls say
Perspective Therapeutics is a promising company with a proprietary technology utilizing lead-212 to deliver radiation specifically to cancer cells, potentially maximizing efficacy and minimizing side effects. With a pipeline targeting various types of cancer, a strong manufacturing network, and a potential market of $6 billion for its PSV594 candidate, Perspective Therapeutics is positioned for success. However, risks include competition and potential challenges in reimbursement and adoption of its products. With promising data and regulatory catalysts expected in 2026, the stock may continue to appreciate.
Bears say
Perspective Therapeutics is a clinical-stage biotech company with a TAT platform that utilizes a proprietary chelation technology optimized for lead. They have a strong focus on developing treatments for various cancers using their alpha-emitting isotope Lead-212 technology. While the company's technology has potential, their reliance on a single platform and the uncertainty of successful clinical trials make it a high-risk investment option.
This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
CATX Analyst Forecast & Price Prediction
Start investing in CATX
Order type
Buy in
Order amount
Est. shares
0 shares